Abstract by Ashley Markham
Chemistry and Biochemistry
Pam Van Ry
Proteomic Analysis for Treatment of Limb-Girdle Muscular Type 2B Model with Galectin-1
Limb-girdle muscular dystrophy type 2B (LGMD2B) is dysferlinopathic muscular dystrophy which affects 1:1,300 to 1:200,000 people every year in the muscles of the limbs and girdles, beginning in adolescence with chronic progression. Dysferlin seems to be involved with membrane repair, but how mutations to the dysferlin gene (DYSF) result in LGMD2B is unknown. The purpose of this research is to identify changes in the proteome of dysferlin deficient cells with an upcoming therapeutic, galectin-1, to increase membrane repair in muscular dystrophy models. We used proteomic analysis to identify proteins whose regulation and turnover rate was different through treatment with galectin-1. We found upregulated proteins in areas of cellular migration and cellular differentiation. Our research provides an insight into how galectin-1 is modifying the capacity and function of dysferlinopathic muscle cells.